UK puts AI medical devices under lifetime monitoring ahead of December's draft guidance

The change is in when a developer has to produce evidence. The regime is moving away from relying heavily on one assessment before an AI device enters the market and toward monitoring how it performs throughout its working life ^[2]. For a health-tech firm, the cost of showing that a product works stops being a launch expense and becomes a running one. The MHRA has yet to publish its guidance on AI devices that change and improve over time ^[4].

That guidance will have to settle between two stated positions. Steve Lee, executive director of regulation at the Association of British Healthtech Industries, called the plans a "positive direction of travel for Healthtech companies and investors" but warned that "continuous oversight should not mean continuous regulatory burden" ^[13][7]. James Frith, the health innovation minister, said the government wanted patients to benefit from AI more quickly but that "innovation must never come at the expense of patient safety" ^[10].

In return, firms get a place to prove their products early. Martin Turner, director of policy and external affairs at the Bioindustry Association, told City AM: "Taking pro-innovation approaches such as this gives UK innovators a competitive edge, as they get to test and develop their products in collaboration with the regulator and gain proof of concept in a large healthcare system, often before their international peers" ^[12]. A skeptic would say that testing alongside a regulator is a different thing from selling to the NHS. Lee made that point himself: "Regulation is also only part of the picture, companies still need a viable route into NHS adoption and procurement if innovation is to translate into commercial growth" ^[8].

The trade-off for a developer is a recurring evidence bill paid in exchange for earlier proof of concept. Turner expects investors to reward that exchange. "The MHRA's approach should enable faster demonstration of concept and value, which we expect will lead to greater investment and acquisitions in the months and years ahead," he said ^[14].

The timetable sets the order of decisions. Firms picked next month for the airlock's third phase will work on post-deployment monitoring with the regulator before the draft guidance appears ^[3][4]. Firms that stay out will plan against whatever that draft says. The consultation on how to classify these products comes later still, next year ^[4]. In my view, a lifetime-monitoring figure in a budget set this quarter is an estimate until the draft is out, and the MHRA has given December as its deadline ^[4].